×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
FDA grants orphan drug designation to ADV7103 for cystinuria
Urology Times
ADV7103 is currently being studied in the phase 2/3 CORAL-1 study, enrolling patients with cystinuria across centers in France and Belgium.
1 month ago
Advicenne S.A. (EPA:ALDVI) Is Expected To Breakeven In The Near Future
Simply Wall Street
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. The €25m market-...
3 months ago
Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries
Business Wire
Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries. - Expanded collaboration now includes Ireland, Cyprus...
6 months ago
Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children
Labiotech.eu
Advicenne is launching an IPO on Euronext Paris to raise the funds to bring the first treatment for dRTA, a rare disease of the kidneys,...
22 months ago
Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region
BioSpace
Sibnayal™ is the first and only label-approved drug for the treatment of Distal renal tubular acidosis (dRTA) in adults, adolescents, and...
27 months ago
Avanzanite Bioscience Partners With Advicenne to Commercialize Sibnayal® For the Treatment of Rare Kidney ...
Business Wire
Avanzanite's Founder and CEO, Adam Plich, stated, “Today's announcement is in lock-step with our purpose – both ethical and economic – of...
14 months ago
FrostPharma to sell Advicenne's Sibnayal in Nordic nations
The Pharma Letter
Sibnayal is the first and only label-approved drug for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents, and...
27 months ago
Advicenne Might Bring the First Drug for This Rare Kidney Disease
Labiotech.eu
Advicenne has announced positive Phase III results for ADV7103, which could soon become the first drug approved for distal renal tubular...
22 months ago
Advicenne: l'ADV7103 désigné médicament orphelin aux Etats-unis
Boursorama
(AOF) - Advicenne annonce que son médicament ADV7103 a obtenu de la FDA le statut de médicament orphelin (Orphan Drug Designation - ODD)...
1 month ago
Advicenne confronté à des discussions compliquées sur la question des remboursements
Les Echos
L'action de la biotech spécialisée dans les maladies du rein chute en Bourse. Si l'activité est au rendez-vous, la société rencontre des...
3 months ago